Oruka Therapeutics
ORKA· Manufacturing· Fiscal year ends in December
Lawrence Klein is the CEO of Oruka Therapeutics and was paid $3.4M in FY2025 (Dec), up 544%.
Executives3
See all- 1Lawrence KleinChief Executive OfficerFY2025
- 2Joana GoncalvesChief Medical OfficerFY2025
- 3Paul QuinlanGeneral CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allOruka Therapeutics paid its 3 named executives $8.0M in total in FY2025 (Dec). CEO Lawrence Klein was paid $3.4M of that.
| Name | |||
|---|---|---|---|
| Lawrence KleinChief Executive Officer | Not disclosed | ||
| Joana GoncalvesChief Medical Officer | Not disclosed | ||
| Paul QuinlanGeneral Counsel | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of Oruka Therapeutics names 18 peer companies for pay. Among Oruka Therapeutics and these peers, CEO pay was the lowest of 5 and total shareholder return was 4th highest of 5.
5th highest of 5in Oruka Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
4th highest of 5in Oruka Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 17, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 18, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | Oct 18, 2024 | — |
| Annual report | 10-K | Feb 1, 2024 | FY2023 |
